Cargando…

Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial

BACKGROUND: Two most important factors determining treatment success in chronic myeloid leukemia (CML) are adequate medication compliance and molecular monitoring albeit still being suboptimal. The CMyLife platform is an eHealth innovation, co-created with and for CML patients, aiming to improve the...

Descripción completa

Detalles Bibliográficos
Autores principales: Verweij, Lynn, Ector, Geneviève I. C. G., Smit, Yolba, van Vlijmen, Bas, van der Reijden, Bert A., Hermens, Rosella P. M. G., Blijlevens, Nicole M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994406/
https://www.ncbi.nlm.nih.gov/pubmed/36890512
http://dx.doi.org/10.1186/s12913-023-09153-9
_version_ 1784902625518419968
author Verweij, Lynn
Ector, Geneviève I. C. G.
Smit, Yolba
van Vlijmen, Bas
van der Reijden, Bert A.
Hermens, Rosella P. M. G.
Blijlevens, Nicole M. A.
author_facet Verweij, Lynn
Ector, Geneviève I. C. G.
Smit, Yolba
van Vlijmen, Bas
van der Reijden, Bert A.
Hermens, Rosella P. M. G.
Blijlevens, Nicole M. A.
author_sort Verweij, Lynn
collection PubMed
description BACKGROUND: Two most important factors determining treatment success in chronic myeloid leukemia (CML) are adequate medication compliance and molecular monitoring albeit still being suboptimal. The CMyLife platform is an eHealth innovation, co-created with and for CML patients, aiming to improve their care, leading to an increased quality of life and the opportunity of hospital-free care. OBJECTIVE: To explore the effectiveness of CMyLife in terms of information provision, patient empowerment, medication compliance, molecular monitoring, and quality of life. METHODS: Effectiveness of CMyLife was explored using a patient-preference trial. Upon completion of the baseline questionnaire, participants actively used (intervention group) or did not actively use (questionnaire group) the CMyLife platform for at least 6 months, after which they completed the post-intervention questionnaire. Scores between the intervention group and the questionnaire group were compared with regard to the within-subject change between baseline and post-measurement using Generalized Estimating Equation models. RESULTS: At baseline, 33 patients were enrolled in the questionnaire group and 75 in the intervention group. Online health information knowledge improved significantly when actively using CMyLife and patients felt more empowered. No significant improvements were found regarding medication compliance and molecular monitoring, which were already outstanding. Self-reported effectiveness showed that patients experienced that using CMyLife improved their medication compliance and helped them to oversee their molecular monitoring. Patients using CMyLife reported more symptoms but were better able to manage these. CONCLUSIONS: Since hospital-free care has shown to be feasible in time of the COVID-19 pandemic, eHealth-based innovations such as CMyLife could be a solution to maintain the quality of care and make current oncological health care services more sustainable. TRIAL REGISTRATION: ClinicalTrials.gov NCT04595955, 22/10/2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-09153-9.
format Online
Article
Text
id pubmed-9994406
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99944062023-03-09 Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial Verweij, Lynn Ector, Geneviève I. C. G. Smit, Yolba van Vlijmen, Bas van der Reijden, Bert A. Hermens, Rosella P. M. G. Blijlevens, Nicole M. A. BMC Health Serv Res Research BACKGROUND: Two most important factors determining treatment success in chronic myeloid leukemia (CML) are adequate medication compliance and molecular monitoring albeit still being suboptimal. The CMyLife platform is an eHealth innovation, co-created with and for CML patients, aiming to improve their care, leading to an increased quality of life and the opportunity of hospital-free care. OBJECTIVE: To explore the effectiveness of CMyLife in terms of information provision, patient empowerment, medication compliance, molecular monitoring, and quality of life. METHODS: Effectiveness of CMyLife was explored using a patient-preference trial. Upon completion of the baseline questionnaire, participants actively used (intervention group) or did not actively use (questionnaire group) the CMyLife platform for at least 6 months, after which they completed the post-intervention questionnaire. Scores between the intervention group and the questionnaire group were compared with regard to the within-subject change between baseline and post-measurement using Generalized Estimating Equation models. RESULTS: At baseline, 33 patients were enrolled in the questionnaire group and 75 in the intervention group. Online health information knowledge improved significantly when actively using CMyLife and patients felt more empowered. No significant improvements were found regarding medication compliance and molecular monitoring, which were already outstanding. Self-reported effectiveness showed that patients experienced that using CMyLife improved their medication compliance and helped them to oversee their molecular monitoring. Patients using CMyLife reported more symptoms but were better able to manage these. CONCLUSIONS: Since hospital-free care has shown to be feasible in time of the COVID-19 pandemic, eHealth-based innovations such as CMyLife could be a solution to maintain the quality of care and make current oncological health care services more sustainable. TRIAL REGISTRATION: ClinicalTrials.gov NCT04595955, 22/10/2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-09153-9. BioMed Central 2023-03-08 /pmc/articles/PMC9994406/ /pubmed/36890512 http://dx.doi.org/10.1186/s12913-023-09153-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Verweij, Lynn
Ector, Geneviève I. C. G.
Smit, Yolba
van Vlijmen, Bas
van der Reijden, Bert A.
Hermens, Rosella P. M. G.
Blijlevens, Nicole M. A.
Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial
title Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial
title_full Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial
title_fullStr Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial
title_full_unstemmed Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial
title_short Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial
title_sort effectiveness of digital care platform cmylife for patients with chronic myeloid leukemia: results of a patient-preference trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994406/
https://www.ncbi.nlm.nih.gov/pubmed/36890512
http://dx.doi.org/10.1186/s12913-023-09153-9
work_keys_str_mv AT verweijlynn effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial
AT ectorgenevieveicg effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial
AT smityolba effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial
AT vanvlijmenbas effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial
AT vanderreijdenberta effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial
AT hermensrosellapmg effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial
AT blijlevensnicolema effectivenessofdigitalcareplatformcmylifeforpatientswithchronicmyeloidleukemiaresultsofapatientpreferencetrial